Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Outlook Therapeutics Inc banner

Outlook Therapeutics Inc
SWB:41ON

Watchlist Manager
Outlook Therapeutics Inc Logo
Outlook Therapeutics Inc
SWB:41ON
Watchlist
Price: 0.1954 EUR -0.96% Market Closed
Market Cap: €2.5m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Gross Profit
Loading...
Operating Income
Loading...
Pre-Tax Income
Loading...
Net Income
Loading...

Wall St Price Targets

41ON Price Targets Summary
Outlook Therapeutics Inc

Wall Street analysts forecast 41ON stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 41ON is 0.755 EUR with a low forecast of 0.0897 EUR and a high forecast of 1.1191 EUR.

41ON Lowest Forecast
0.0897 EUR
-54% Downside
41ON Average Forecast
0.755 EUR
286% Upside
41ON Highest Forecast
1.1191 EUR
473% Upside
Lowest Forecast
Price Target
0.0897 EUR
54% Downside
Average Forecast
Price Target
0.755 EUR
286% Upside
Highest Forecast
Price Target
1.1191 EUR
473% Upside
Outlook Therapeutics Inc Competitors:
Price Targets
CFFN
Capitol Federal Financial Inc
3% Upside
B
BRI
Britania PCL
12% Upside
ELAN
Elanco Animal Health Inc
27% Upside
AMSF
Amerisafe Inc
20% Upside
CFFN
Capitol Federal Financial Inc
3% Upside
B
BRI
Britania PCL
12% Upside
ELAN
Elanco Animal Health Inc
27% Upside
AMSF
Amerisafe Inc
20% Upside
VNOM
Viper Energy Partners LP
36% Upside
L
LGI
Lgi Ltd
43% Upside

Revenue
Forecast

-12% / Year
Past Growth
55% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
-12% / Year
Past Growth
55% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 10 years, the compound annual growth rate for Revenue has been -12%. The projected CAGR for the next 8 years is 55%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Outlook Therapeutics Inc

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Outlook Therapeutics Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-92%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-92%
Average Miss

What are analyst estimates?

See Also

Summary
41ON intrinsic value, competitors valuation, and company profile.
DCF Valuation
41ON stock valuation using Discount Cash Flow valuation method.
Relative Valuation
41ON stock valuation using valuation multiples.
Wall St Estimates
41ON price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
41ON stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Outlook Therapeutics Inc listings:
NASDAQ • USD
OTLK
 F • EUR
41ON
 F • EUR
41O
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 41ON's stock price target?
Price Target
0.755 EUR

According to Wall Street analysts, the average 1-year price target for 41ON is 0.755 EUR with a low forecast of 0.0897 EUR and a high forecast of 1.1191 EUR.

What is the Revenue forecast for Outlook Therapeutics Inc?
Projected CAGR
55%

Over the last 10 years, the compound annual growth rate for Revenue has been -12%. The projected CAGR for the next 8 years is 55%.

Back to Top
ALPHA SPREAD
Follow us
Join 342,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett